Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Rare Tumors Involving Bone–Insight into Their Biology, Novel Diagnostic and...
share announcement

Rare Tumors Involving Bone–Insight into Their Biology, Novel Diagnostic and Therapeutic Tools, including Targeted Therapies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Pediatric Oncology".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 2310

Special Issue Editors

Dr. Agnieszka Śmieszek

E-Mail Website
Guest Editor
Department of Experimental Biology, The Faculty of Biology and Animal Science, University of Environmental and Life Sciences, Norwida St. 27B, 50-375 Wroclaw, Poland
Interests: osteosarcoma; histiocytosis; osteoblatsts and osteoclasts coupling; bone homeostasis; cell biology; non-coding RNA; targeted cancer therapy; non-invasive biomarkers
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Anna Raciborska

E-Mail Website
Guest Editor
The Institute of Mother and Child, Kasprzaka St. 17a, 01-211 Warsaw, Poland
Interests: osteosarcoma; Ewing sarcoma; bone and soft tissue sarcoma; histiocytosis; clinical studies; advanced therapies in pediatric oncology; precise diagnostics

Special Issue Information

Dear Colleagues,

We are pleased to invite you to share your research and contribute to this special issue devoted to rare tumors involving bone tissue. Tumors that occur in fewer than 15 out of 100 000 people each year are defined by National Cancer Institute as rare cancer. Pediatric uncommon primary cancers affecting bone include osteosarcoma, Ewing sarcoma, chondrosarcoma but also histiocytosis, primary bone lymphoma, and other very rare neoplasms. Treatment of rare cancer associated with the bone is particularly challenging due to often late and incorrect diagnosis and limited preclinical studies on novel, cost-effective therapeutic strategies. 

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the most current studies aimed at developing methods for precise diagnosis of rare bone-associated cancers and research on targeted and personalized therapies. Great emphasis will be put on the biology and molecular pathogenesis of rare cancers affecting bone, as these studies guarantee advancements in the development of new precise treatment methods. This special issue will also focus on the role of non-coding RNAs in the pathogenesis of rare cancers associated with bone, introducing long non-coding RNAs (lncRNA) and small non-coding RNAs as potentially sensitive and reliable non-invasive biomarkers or therapeutic targets.

We look forward to receiving your contributions.

Dr. Agnieszka Śmieszek
Prof. Dr. Anna Raciborska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rare bone involving tumors
  • osteosarcoma
  • Ewing sarcoma
  • chondrosarcoma 
  • histiocytosis
  • primary bone lymphoma
  • targeted therapies and personalized therapies
  • precise diagnostics
  • cancer cell biology
  • circulating and tissue-specific molecular biomarkers, including non-coding RNA

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 1931 KiB  
Article
Comparison of Selected Non-Coding RNAs and Gene Expression Profiles between Common Osteosarcoma Cell Lines
by Mateusz Sikora, Katarzyna Krajewska, Klaudia Marcinkowska, Anna Raciborska, Rafał Jakub Wiglusz and Agnieszka Śmieszek
Cancers 2022, 14(18), 4533; https://doi.org/10.3390/cancers14184533 - 19 Sep 2022
Cited by 1 | Viewed by 1951
Abstract
Osteosarcoma (OS) is a bone tumour affecting adolescents and elderly people. Unfortunately, basic treatment methods are still underdeveloped, which has a high impact on the poor survivability of the patients. Studies designed to understand the underlying mechanisms of osteosarcoma development, as well as [...] Read more.
Osteosarcoma (OS) is a bone tumour affecting adolescents and elderly people. Unfortunately, basic treatment methods are still underdeveloped, which has a high impact on the poor survivability of the patients. Studies designed to understand the underlying mechanisms of osteosarcoma development, as well as preclinical investigations aimed at establishing novel therapeutic strategies, rely significantly upon in vitro models, which apply well-established cell lines such as U-2 OS, Saos-2 and MG-63. In this study, the expression of chosen markers associated with tumour progression, metastasis and survival were identified using RT-qPCR. Levels of several onco-miRs (miR-21-5p, miR-124-3p, miR-223-3p and miR-320a-3p) and long non-coding RNA MEG3 were established. The mRNA expression of bone morphogenetic proteins (BMPs), including BMP-2, BMP-3, BMP-4, BMP-6, BMP-7, as well as their receptors: BMPR-IA, BMPR-IB and BMPR-II was also determined. Other tested markers included metalloproteinases, i.e., MMP-7 and MMP-14 and survivin (BIRC5), C-MYC, as well as CYCLIN D (CCND1). The analysis included comparing obtained profiles with transcript levels established for the osteogenic HeLa cell line and human adipose-derived stromal cells (hASCs). The tested OS cell lines were characterised by a cancer-related phenotype, such as increased expression of mRNA for BMP-7, as well as MMP-7 and MMP-14. Osteosarcoma cells differ considerably in miR-21-5p and miR-124-3p levels, which can be related to uncontrolled tumour growth. The comprehensive examination of osteosarcoma transcriptome profiles may facilitate the selection of appropriate cell models for preclinical investigations aimed at the development of new strategies for OS treatment. Full article
(This article belongs to the Special Issue Rare Tumors Involving Bone–Insight into Their Biology, Novel Diagnostic and Therapeutic Tools, including Targeted Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop